Guinea-Bissau Hepatitis B Vaccine Trial: Suspension or Cancellation – Uncertainty Remains
News Context
At a glance
- Confusion surrounds a controversial clinical trial in Guinea-Bissau.
- In Guinea-Bissau, announcements have come quickly: maintained, suspended, canceled?
Confusion surrounds a controversial clinical trial in Guinea-Bissau. A Danish team, funded by the United States, is studying 14,000 newborns. Half received a hepatitis B vaccine at birth, while the others wait six weeks. This practice draws criticism in a country where nearly 20% of the population carries the virus.
Published: January 23, 2026 – 01:13
Reading time: 2 min
In Guinea-Bissau, announcements have come quickly: maintained, suspended, canceled? The Africa CDC (African Center for Disease Control and Prevention) held a press conference Thursday, January 22, to clarify the situation.